mRNA technology shows promise in cancer vaccine development

Messenger RNA (mRNA) technology, which gained global prominence during the COVID-19 pandemic, is showing significant promise in the development of cancer vaccines. Since 2000, over one hundred clinical trials have utilized mRNA technology to target various cancers, including skin, brain, breast, lung, pancreas, and prostate cancers.

These vaccines function by delivering specific instructions to cells, enabling the immune system to recognize and destroy tumor cells while sparing healthy tissue. Recent clinical results involving personalized mRNA vaccines combined with immunotherapy have demonstrated a significant reduction in melanoma recurrence.

The foundational research behind mRNA technology was recognized with the 2023 Nobel Prize in Physiology or Medicine, awarded to Katalin Karikó and Drew Weissman. Despite these scientific advancements, progress faces challenges from health misinformation, such as the unfounded ‘turbo cancer’ theory.